BOARD OF DIRECTORS
Kenneth A. Lynch, CPA, MT is Assistant Vice President for Financial Reporting and Risk Management at South Jersey Industries, Inc. He has 20 years of experience performing assurance services and advising companies on complex financial issues. Formerly a Senior Manager in the Entrepreneurial Services Group of Ernst and Young LLP, Ken has served a wide range of clients from closely held, emerging growth companies to multi-national, publicly traded entities. These clients have primarily been in the manufacturing, retail, distribution, software, service and technology industries. Ken has assisted numerous clients as they enter into significant transactions such as mergers, acquisitions and public offerings.
Charles
P. O’Brien, MD, PhD is Chief of Psychiatry at the
Philadelphia VA Medical Center, and Vice-Chair of Psychiatry at the University
of Pennsylvania where he is also Director of the Center for Studies of
Addiction. O’Brien was elected to the Institute of Medicine of the
National Academy of Sciences in 1991, and has received numerous national
research awards as well as an honorary Doctorate from the University of
Bordeaux in 1994 and the Nathan P. Eddy award for research on addiction
from the College on Problems of Drug Dependence. O’Brien’s
research focus is on discovery of changes to the central nervous system
involved in relapse, new medications, behavioral treatments, and instruments
for measuring the severity of addictive disorders. He is past President
of both the American College of Neuropsychopharmacology and the Association
for Research in Nervous and Mental Disease.
Stephen
J. Pasierb, MEd, is President and CEO of the Partnership
for a Drug-Free America. He joined the Partnership in 1993, was named
to the Board of Directors in 2000, and became president in October 2001.
Under Steve’s leadership, the Partnership coordinates combined substance
abuse education campaigns which garner annual media donations totaling
$400 million. Operationally, the Partnership has produced five consecutive
years of double digit revenue growth, leveraging every donated dollar
into 38 dollars of program services. The organization has continued its
unprecedented record of effectiveness, as confirmed via research, most
recently with a program addressing Ecstasy that helped drive down teen
usage of this illicit drug by 50 percent, as well as launched an innovative
education initiative on addiction intervention and treatment (Hope, Help
& HealingTM™) while supporting parents as they strive to raise
healthy, drug-free kids (Partnering with FamiliesTM™). In 2004,
the Partnership was one of 13 organizations world-wide to receive the
Discovery Health Medical Honors award for its extraordinary contributions
to world health. The Partnership has been rated 4 stars — the highest
rating — from Charity Navigator for efficient use of donor funding.
And, the New York Times has called the Partnership, "One of the most
effective drug prevention organizations in the U.S."
George E. Woody, MD
is a Professor in the Department of Psychiatry at the University of Pennsylvania
with 35 years of specialized research on treatment efficacy in substance
abuse. Among his notable achievements are founding member of the Board
of Addiction Psychiatry of the American Psychiatric Association, two-time
member of the Board of Directors of the College on Problems of Drug Dependence,
and Life Fellow of the American Psychiatric Association. He is currently
Director of the Delaware Valley Node of the NIDA-funded Clinical Trials
Network.
Behavioral
Interventions
Law
& Ethics
Treatment
Systems Research
Center
on the Continuum of Care:
Monitoring
and Adapting Addiction Treatment
Center
for Policy Research and
Analysis
Adolescents
Treatment
Research Solutions
Wharton-TRI
Center on the
Organization
and Management of Addiction Treatment
Clinical
Trials Network
Addiction
Severity Index (ASI)
Other
Assessment Instruments
Publications
Presentations
Archives
Training
Order
TRI Resources
Contact
Us
Sign
up for E-Alerts
Research
Briefs